← All trials
NCT07070752
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 14, 2023
- Primary completion
- Nov 28, 2023
- Completion date
- Nov 28, 2023
- First posted
- Jul 17, 2025
- Last posted
- Jul 22, 2025
- Enrollment
- 224
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GeropharmLead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.